Screening for coeliac disease among Egyptian children by Abd El Dayem, Soha M. et al.
Screening for coeliac disease among Egyptian children
Soha M. Abd El Dayem
1, Azza Ahmed Aly
2, Esmat Abd El Gafar
2, Hesham Kamel
3
Corresponding author:
Soha M. Abd El Dayem
National Research Centre 
1 Mathaf El Manial Street
Ilhamy Hussein Building 
Flat 52
Cairo, Egypt
Phone: 010 6716852 
E-mail: S_eldayem@yahoo.com 
Original research
1Department of Paediatrics, National Research Centre, Cairo, Egypt
2Department of Clinical and Chemical Pathology, National Research Centre, Cairo, Egypt
3Department of Paediatrics, Cairo University, Egypt
Submitted: 7 May 2008
Accepted: 28 October 2008
Arch Med Sci 2010; 6, 2: 226-235
DOI: 10.5114/aoms.2010.13900
Copyright © 2010 Termedia & Banach
Abstract
Introduction: To screen for coeliac disease in Egyptian children with non-
endocrinal short stature, refractory iron deficiency anaemia and type 1 diabetes.
Also, to evaluate the sensitivity and specificity of different serological tests for
diagnosis of coeliac disease (CD).
Material and methods: The study included 292 patients with clinical risk of CD.
Testing for coeliac antibodies was performed, together with upper gastro  -
intestinal endoscopy and small intestinal biopsy.
Results: Eleven patients (44%) among 25 patients with refractory iron deficiency
anaemia, 23 patients (34.3%) among 67 patients with non-endocrinal short
stature, and 6 patients (3%) among 200 patients with type I diabetes mellitus
were diagnosed by jejunal biopsy as having coeliac disease. AGA (IgG) had the
highest sensitivity for diagnosing CD (80.0%) followed by the TTG (72.7%)
antibody, while ARA had the highest specificity (95.9%) followed by anti-EMA
(94.7%).
Conclusions: Coeliac disease is more common in Egyptian children with refractory
iron deficiency anaemia, non-endocrinal short stature and type 1 diabetes than
was previously thought; therefore it is mandatory to screen such patients for
CD. Serological tests showed fairly good sensitivity and specificity for the
diagnosis; however, intestinal biopsy remains the cornerstone for definitive
diagnosis of patients with immunological reaction to gluten.
Key words: coeliac disease, short stature, insulin-dependent diabetes mellitus,
refractory iron deficiency anaemia.
Introduction
Coeliac disease (CD) is an auto-immune inflammatory reaction
characterized by partial or total atrophy of the proximal small intestinal villi,
occurring after ingestion of gluten in genetically predisposed patients [1, 2].
Inflammatory denudation of the villous surface gives rise to
malabsorption of foodstuffs, folate, fat-soluble vitamins and iron. In
children with severe mucosal damage, absorption of vitamins, zinc and
protein is also affected [3]. It is common in children and adolescents with
a variety of disorders, including children with recurrent or persistent
gastrointestinal symptoms, dermatitis herpetiformis, dental enamel
defects, osteoporosis, short stature, delayed puberty, persistent iron
deficiency anaemia, asymptomatic individuals with type 1 diabetes, Down
syndrome, Turner syndrome, Williams syndrome, selective immunoglobulin
(IgA) deficiency and first degree relatives of individuals with coeliac disease
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Many children and adults with coeliac disease
have non-classical forms of the illness. So-called
silent coeliac disease refers to partial or complete
villous atrophy in seropositive patients who have
no gastrointestinal or extra-intestinal complications.
Subclinical coeliac disease refers to villous atrophy
in seropositive patients who have extra-intestinal
complications but few or no gastrointestinal
complaints [6].
Troncone et al. [7] reported a strong association
between HLA class II genes (Dq molecule) and the
pathogenesis of CD. Recent studies have shown
that in the intestinal mucosa of coeliac patients,
there are T-cells that recognize gliadin peptides
when presented by the Dq heterodimer (A1* 0501,
B1* 0201) [8, 9]. Children with autoimmune
disorders such as type 1 diabetes, autoimmune
thyroid disease and Sjogren’s syndrome have
a higher incidence of coeliac disease [10].
The frequency of cases of CD with atypical
manifestations, especially in older children and
adults, the existence of latent forms of the disease,
and the presence of groups of patients considered
at high risk for developing CD, together with the
need to monitor relapses and compliance to diet in
diagnosed cases, have prompted the search for
non-invasive serological screening methods [11].
The use of serology resulted in an increased
detection rate, although a true increase in incidence
may have also occurred [12].
Although intestinal biopsy is the gold standard
for final diagnosis of CD and it is the only proof of
a positive or negative response to a gluten-free diet
[13], three main categories of circulating antibodies
have been identified with potential value in the
diagnosis and screening of CD: anti-gliadin (AGA),
anti-reticulin (ARA) and anti-endomysial antibodies
(EMA). Anti-endomysial antibodies have largely
replaced anti-reticulin antibodies because of their
greater sensitivity [14].
Tissue transglutaminase (tTG) has been
identified as the main, if not sole, autoantigen
recognized by endomysial antibodies in patients
with CD. This enzyme, which is widely distributed
in human organs, belongs to a family of calcium-
dependent enzymes. IgA class tTG autoantibodies
may be a useful tool in diagnosis and follow-up of
CD [7].
Scientific studies confirm that the average
consumption of wheat of an Egyptian citizen is
150 kg per year. It is available mainly in bread,
macaroni and other packed cake. There are
difficulties in sticking to a gluten-free diet (GFD) in
Egypt, it being less commercially available and more
expensive [15].
Our aim is to screen coeliac disease in Egyptian
children with non-endocrinal short stature,
refractory iron deficiency anaemia and type 1
diabetes; and also to evaluate the sensitivity and
specificity of different serological tests for diagnosis
of CD. 
Material and methods 
It is a case control prospective study done after
obtaining approval from the local institutional
review board and human subjects protection.
Written consent was obtained from patients and
their parents. 
This study included 292 patients, selected from
the outpatient clinic of the National Research Centre
and Cairo University Children’s Hospital from 2004
to 2007. They represented the following groups (the
number in each group related to the willingness of
patients to enter the study and the prevalence of
each disease).
Group I: patients with refractory iron deficiency
anaemia (25 patients)
The study included 25 patients < 18 years of age
with refractory iron deficiency anaemia (not
responding to iron therapy for 3 months in a dose
of 6 mg elemental iron/kg/day).
The diagnosis of iron deficiency anaemia was
based on the presence of haemoglobin concentration
below the cut-off value of < 11 g/dl for children 
5 months to 5 years of age, reduced MCV < 75 fl,
increased RDW > 14.5 and one or more of the
following: serum ferritin < 10 mg/dl (cut-off value of
12 mg/dl), serum iron < 50 µg/dl and transferrin
saturation % (serum iron/TIBC × 100) < 15% [16].
Exclusion criteria
• Prior erosive, ulcerative or malignant disease of
the gastrointestinal tract. 
• Previous gastrointestinal surgery. 
• Overt gastrointestinal bleeding within the past 
3 months. 
• Inability to access the duodenum for biopsy. 
• Patients with parasites causing chronic blood loss,
i.e. Ancylostoma or bilharziasis. 
• Presence of occult blood in stools.
Group II: patients with non-endocrinal short
stature (67 patients)
Inclusion criteria
• Height greater than 2.5 SDS below the mean for
age.
• Growth velocity less than expected for their age.
• Delayed bone age. 
Exclusion criteria
• Familial short stature (according to mid-parental
height). 
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• Constitutional delay of growth and puberty. 
• Dysmorphic syndromes. 
• Disproportional short stature (bone dysplasias
and rickets). 
• Chronic systemic diseases. 
• Patients with endocrinal causes of short stature
(primary hypothyroidism and growth hormone
deficiency disorders in response to stimulation by
ITT and clonidine tests). 
• Turner syndrome diagnosed by karyotype. 
Group III: patients with type I diabetes mellitus
(200 patients)
They were selected among diabetics with
variable duration of disease and variable
glycosylated haemoglobin levels (controlled and
uncontrolled). 
All the above groups were subjected to full
history taking (with special stress on the duration
of disease and relation of symptoms to diet) 
and thorough clinical examination including
anthropometric measurements (mainly weight and
height, or length if needed). Height was determined
with a Harpender stadiometer, weight was taken
with standard underwear using a balance scale
(Sica – company).
Laboratory investigations
For antibody detection 5 ml of blood was
obtained by venepuncture from each patient and
sera were separated promptly, grossly haemolysed
and lipaemic samples were excluded. The
specimens were aliquoted and stored at –20°C until
the time of analysis. 
Laboratory investigations were done in the form
of IgA anti-endomysium for patients with refractory
iron deficiency anaemia and diabetes mellitus, IgA
anti-gliadin for patients with short stature, and IgG
antibodies to tissue transglutaminase for patients
with refractory iron deficiency anaemia, while IgG
anti-gliadin and IgA anti-reticulin was done for all
patients included in the study. 
Anti-gliadin antibody (AGA) detection was
performed by a solid phase enzyme immunoassay
(ELISA), using kits from Immco Diagnostics for IgG
AGA (Immco – USA/ Canada). Anti-reticulin antibody
(ARA) detection was performed by indirect
immunofluorescence using a commercial kit from
Immco Diagnostics (Immco – USA/Canada). Anti-
endomysial antibody (EMA) detection was
performed by indirect immunofluorescence (using
monkey oesophagus as a substrate) using
a commercial kit from Immco Diagnostics (Immco
– USA/ Canada). Anti-tissue transglutaminase (TTG)
IgG antibody detection was performed by an ELISA
technique for the detection and semi-quantitation
of anti-tissue transglutaminase IgG antibodies in
human serum using a commercial kit from Immco
Diagnostics (Immco – USA/Canada).
In addition, upper gastrointestinal endoscopy
with small intestinal biopsies was done for only 98
out of the 292 studied patients. These included all
patients with refractory iron deficiency anaemia
and short stature and only type 1 diabetics with
positive coeliac antibodies that justified the invasive
upper gastrointestinal tract (GIT) endoscopy (only
6 out of the 200 studied patients).
At least two biopsies from the jejunum were
obtained using conventional endoscopic forceps
(open cup 8 mm). Samples were carefully oriented
on filter paper (Millipore) and fixed in 10% formalin.
Biopsies were embedded in paraffin wax, cut in
sections 5 µm thick, and stained with haematoxylin
and eosin. Small bowel biopsies were evaluated by
observers unaware of the clinical and endoscopic
findings.
Coeliac disease was diagnosed with one or more
positive serological tests and typical histological
findings on jejunal biopsy: inflammatory
enteropathy characterized by proliferation of
intraepithelial lymphocytes, crypt hyperplasia and
partial or complete atrophy of small intestinal villi
[17]. Jejunal biopsy is considered the gold standard
for diagnosis of coeliac disease. 
Follow-up biopsy 6-11 months after starting
a gluten-free diet was performed in 9 patients only
(3 patients presenting with short stature and the
remaining 6 with insulin-dependent diabetes
mellitus [IDDM]), while the remaining patients
refused.
As jejunal biopsy is considered the gold standard
and from the ethical point of view we could not
perform biopsy in normal healthy children, patients
with no villous atrophy were considered to be the
control group.
Statistical analysis
Data were summarized as percentages. Weight
and height were transformed into SDS by the
program Growth Vision version 2. Sensitivity,
specificity, negative predictive value (NPV), positive
predictive value (PPV) and diagnostic efficiency of
all antibodies were calculated according to biopsy
results[12].
Sensitivity
Sensitivity is defined analytically as the lowest
amount of the analyte that can be detected.
Epidemiologically, it is the measure of the ability to
detect or identify CD.
Number of true positives
Sensitivity = × 100.
Number of true positives + 
+ number of false negatives
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Specificity
Specificity means, analytically, the degree of
interference in the assay by extraneous substances
that may be present in the sample, and
epidemiologically, it is the ability of the test to
identify the population without CD. Specificity
(negative in health) is calculated as follows:
Number of true negatives
Sensitivity =                                                    × 100.
Number of true negatives + 
+ number of false positives
The predictive values
The positive predictive value is the fraction of
positive test results that are true positives. This is
often rather low in CD markers, when the false
positive rate of the test is high.
Positive                       True positives
predictive =                                                     × 100.
value            True positives + false positives
It is the probability that a person with a positive
result actually has the disease. Similarly, the
negative predictive value is the probability that
a person with a negative result does not have the
disease.
Negative                    True negatives
predictive =                                                     × 100.
value            True negatives + false negatives
Results
This study included 292 patients with clinical risk
of CD divided into 3 groups: group I: refractory iron
deficiency anaemia (25 patients), group II: non-
endocrinal short stature (67 patients) and group III:
type 1 diabetes mellitus (200 patients).
Group I: the 25 patients with refractory iron
deficiency anaemia included in the study (19 males
and 6 females), with mean age 6.5 ±4.5 year 
(1.0-17.0 year), mean age at presentation of
anaemia 1.6 ±0.9 year (1.0-4.0 year) and mean
duration of anaemia 2.8 ±2.5 year (0.2-10.0 year).
The mean height SDS was –1.8 ±2.2 (–5.1-2.8 SDS)
and mean weight SDS was –2.0 ±1.3 (–3.9-1.4 SDS).
Eleven patients (44%) were diagnosed by jejunal
biopsy as having coeliac disease. Table I represents
the symptoms and complications while Table II
represents the endoscopic and histopathological
findings of the 11 coeliac disease patients
presenting with refractory iron deficiency anaemia.
Group II: the 67 short children included in this
study (44 males and 23 females) had a male to
female ratio of 1.9, and a mean age of 7.9 ±3.9 years
(range 2-18 years), mean height of –3.5 ±0.7 SDS
(range [–2.5]-[–5.0]), mean weight of –2.7 ±1 SDS
and mean growth velocity 4.3 ±1.2 cm/year.
Twenty-three patients (34.3%) were diagnosed
by jejunal biopsy as having coeliac disease. Fifteen
patients out of the 23 (65.2%) had short stature as
the only presentation. The rest had short stature in
addition to other presentations (Table III).
• Cases no. 1, 3, 8 and 13 (17.4%) had chronic
diarrhoea with an age of onset less than 2 years. 
• Case no. 3 had chronic diarrhoea and congenital
myopathy. 
• Case no. 9 had persistent hypocalcaemia and 
X-ray revealed osteoporosis. 
• Case no. 5, 6 had anaemia and hepatomegaly and
case no. 6 had atrial septal defect (ASD).
• Case no. 12 had failure to thrive. 
Group III: it included 200 patients with IDDM (116
females and 84 males) with mean chronological age
of 11.4 year. Prevalence of CD among the 200 IDDM
cases was 3% (6 cases), 5 female patients and 
1 male patient with male/female ratio of 1/5. Table IV
shows the clinical data while Table V shows the
Variables Coeliac
[N = 11]
N %
Anorexia 5 45.5
Heartburn 3 27.3
Dyspepsia 3 27.3
Vomiting 2 18.2
Abdominal distension 2 18.2
Abdominal pain 7 63.6
Diarrhoea 5 45.5
Underweight* 3 27.3
Short Stature# 5 45.5
Haematemesis 0 0
Table I. Symptoms and complications of coeliac
disease in patients presenting with refractory iron
deficiency anaemia 
*Underweight = weight ≥ –2.5 (SDS) below the mean
#Short stature = height ≥ –2.5 (SDS) below the mean
Variables Coeliac Non-coeliac
[N = 11] N = 14
N % N %
Oesophagitis 3 27.3 8 57.1
Gastritis 5 45.5 6 42.9
Duodenitis 10 90.9 10 71.4
Jejunitis 10 90.9 6 42.9
J. Inflammation# 6 54.5 12 85.7
Table II. Study of endoscopic and histopathological
findings of coeliac and non-coeliac disease patients
presenting with refractory iron deficiency anaemia
#Jejunal inflammation was detected by histopathological examination
of jejunal biopsieslaboratory data of the 6 CD patients presenting
with IDDM. 
AGA (IgG) showed the highest sensitivity (80%)
followed by TTG (72.7%). ARA (IgA) showed the
highest specificity (95.6%) followed by EMA (94.7%)
(Table VI). 
Discussion
Coeliac disease or gluten sensitive enteropathy
is a permanent intolerance of dietary gluten
leading to mucosal damage in the proximal small
bowel in genetically susceptible individuals,
characterized by inflammation, crypt hyperplasia
and villous atrophy which regress on withdrawal of
gluten from the diet [17].
Ravikumara et al. [8] found the prevalence of CD
in the Avon longitudinal study of parents and
children to be at least 1%, and more than 90% of
cases of CD in children pass undiagnosed. 
In our study, CD was diagnosed in 11 (44.0%) out
of the 25 refractory iron deficiency anaemia (IDA)
studied patients.
The anaemia of CD can be microcytic or
macrocytic, and both iron and folic acid deficiencies
have been described. Iron deficiency is commonly
seen in CD because of the frequent involvement of
the proximal small intestine, where most iron
No. Age Sex Presentation other than AGA-IgG AGA-IgA ARA-IgA Biopsy Follow-up biopsy
[year] short stature
1 12 M Ch. diarrhoea 4 ve +ve +ve Grade III (V.A.) –
2 9 F 113.1* 129.5* +ve Grade III (V.A.) –
3 7.5 F Ch. diarrhoea + myopathy 253* 268* –ve Grade III V.A. Grade II V.A. 
myopathy 
improved
4  10 M 12.5  19.4  –ve Grade I V.A.  –
5 12 M Anaemia, hepatomegaly 160.7* 20 –ve Grade II V.A. –
6 6.7 M Anaemia, hepatomegaly + A.S.D. 96* 15.5 –ve Grade II V.A. –
7 6.9 M 4.5 18.5 –ve Grade I V.A. –
8 5 M Ch. diarrhoea 205.9* 11.6 –ve Grade II V.A. The condition 
improved after 
gluten-free diet 
before biopsy
9 14 M Pain in L.L. and persistent  +ve –ve +ve Grade III V.A. N. Intestine 
hypocalcaemia N. Ca level
10 7 M +ve –ve –ve Grade I V.A. N. Intestine
11 8 M 151* –ve +ve Grade III V.A.
12 11.8 F Failure to thrive* 69* +ve +ve Grade I V.A.
13 6 F Vomiting diarrhoea 310* –ve +ve Grade III V.A.
14 10.5 F 116* 136* +ve Grade III V.A.
15 5 F 75* – +ve Grade III V.A.
16 10.4 M 87.2* 68* +ve Grade III V.A.
17 6.1 M 78.4* 26.5 –ve Grade II V.A.
18 4.3 F 24.6 7 +ve Grade I V.A.
19 3 M 302* 17 +ve Grade III V.A.
20 6 M 321.4* 37.5 +ve Grade III V.A.
21 5  F 36 40 –ve Grade I V.A.
22 4 M 192* 47.5 –ve Grade II V.A.
23 6 M 128* 45 –ve Grade II V.A.
*Positive ASD: atrial septal defect, V.A. – villous atrophy AGA: anti-gliadin antibody, S.S. – short stature ARA: anti-reticulin antibody 
Table III. Demographic data and serological tests of patients with positive biopsy for coeliac disease presenting with
short stature 
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Case no. Sex CA  Age of onset  Duration of  GIT symptoms Height SDS Weight SDS
(Y) IDDM (Y) DM (Y)
I F 10.0 1.0 Repeated  vomiting
• before GFD 11 +0.25  +0.5 
• after GFD 11.75 +0.25 +0.75
II F 12.0 2.0 Abdominal  distension
• before GFD 14.0 –0.25  +0.75 
• after GFD 14.75 –0.25 +1.25
III F 1.0 11.42 Recurrent  diarrhoea
• before GFD 12.42 –1.75  +0.5 
• after GFD 13.33 –2.0 +0.75
IV F 3.0 6.0 Recurrent  diarrhoea
• before GFD 9.0  & distension –2.75  –2.5 
• after GFD 9.92 –3.0 –2.0
V  F 5.0 8.5 No GIT symptoms
• before GFD 13.5  –2.25  –1.75
• after GFD 14.42 –2.0 –0.5
VI M 4.0 12.25 Persistent  diarrhoea
• before GFD 16.25  –3.5  –3.5 
• after GFD 17.0 –3.25 –3.5
*CA – chronological age, GIT – gastrointestinal tract, F – female, M – male, GFD – gluten-free diet
Table IV. Clinical data of coeliac disease patients with insulin-dependant diabetes mellitus 
Case no. Hb [g%] HbA1c [%] AGA [Eu/ml]A RAE MAB i o p s y
I  Grade III 
• before GFD 12.0  10.5  6.0  +ve  +ve V.A
• after GFD 12.3 10.0 4.5 +ve +ve
II  Grade II 
• before GFD 11.5  11.1  6.2  –ve  +ve  V.A
• after GFD 11.8 11.7 5.8 –ve +ve
III  Grade II
• before GFD 11.6  12.0  11.6  +ve  –ve  V.A
• after GFD 12.0 11.5 10.0 +ve –ve
IV  Grade II & III 
• before GFD 11.5  10.5  30  +ve  +ve  V.A
• after GFD 12.0 11.2 28 +ve +ve
V  Grade II 
• before GFD 12.0  10.7  8.6  +ve  –ve  V.A
• after GFD 11.5 8.9 6.0 +ve –ve
VI  Grade II 
• before GFD 6.5  8.7  34  –ve  –ve  V.A
• after GFD 10.0 6.9 38 –ve –ve
V.A – villous atrophy, GFD – gluten-free diet, AGA – anti-gliadin antibody, ARA – anti-reticulin antibody, EMA – endomysium antibody
Table V. Laboratory data of coeliac disease patients with insulin-dependant diabetes mellitus 
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Antibody Sensitivity [%] Specificity [%] PPV [%] NPV [%] Accuracy [%]
AGA (IgA)  17.0 93.2 57.1 68.3 67.2
AGA (IgG)  80.0 92.9 64.0 96.7 91.1
ARA (IgA)  57.5 95.6 67.6 93.4 90.4
EMA (IgA)  70.6 94.7 52.2 97.5 92.9
TTG (IgG)  72.7 85.7 80.0 80.0 80.0
PPV – positive predictive value, NPV – negative predictive value, AGA – anti-gliadin antibodies, ARA – anti-reticulin antibodies, 
AEM – anti-endomysium antibodies, TTG – anti-tissue transglutaminase
Table VI. Sensitivity, specificity, PPV, NPV and accuracy of different antibodies of all studied patients. Total studied
group (Total No. = 292)
absorption occurs [19]. Because CD may result in
intestinal malabsorption of iron, occult coeliac
disease has been reported in 0 to 6% of adults
presenting with iron deficiency anaemia (IDA) [20].
On the other hand, the reported incidence of IDA in
CD varies between 10 and 80%, depending on the
diagnostic criteria used [21]. Fisgin et al. [22],
Masjedizadeh et al. [4], and Kalayci et al. [23]
reported an incidence of 54.5, 3.2 and 66.7%
respectively of IDA in a group of children with CD,
which is much higher than in the general population.
In the current study, the most common reported
symptoms in patients with CD presenting with
refractory IDA were: gastrointestinal symptoms in
the form of abdominal pain (63.6%), diarrhoea and
anorexia (45.5% each), dyspepsia and heartburn
(27.3% each), vomiting and abdominal distension
(18.2% each). Complications detected in those
patients were short stature (45.5%), and
underweight (27.3%). Mody et al. [21] suggested
that, although the association of IDA with CD is
recognized, the setting is usually that of significant
gastrointestinal symptoms and malabsorption and
not a sole presenting sign.
Endoscopic and histopathological findings
detected in patients with CD were duodenitis and
jejunitis (90.9% each), gastritis (45.5%), oeso  -
phagitis (27.3%), hiatus hernia (18.2%) and jejunal
inflammation detected by histopathological
examination of jejunal biopsies (54.5%).
Bhadad et al. [24] suggested that CD emerged
as the single most common cause of short stature,
followed by various endocrine disorders. Short
stature by itself, even when GIT symptoms are
totally absent, is an appropriate indication for
jejunal biopsy.
Our study on group II patients (patients with
non-endocrinal short stature) showed that 23
(34.3%) out of 67 biopsied cases revealed total or
subtotal villous atrophy diagnostic of CD. Our results
are in agreement with De Lecea et al. [25], who
reported an incidence of CD in short children
ranging from 25 to 33.8%, while lower prevalence
(12%) was reported by Czerwionka-Szaflarska et al.
[26]. This high prevalence of CD in our study may
be related to the selection of a high risk group of
short children after exclusion of endocrinal causes
of short stature.
In the current study, follow-up intestinal biopsy
was done for only 3 patients with non-endocrinal
short stature who received a gluten-free diet (GFD)
for 6 months following the first biopsy. Case no. 10,
who presented with only short stature, showed
normal intestinal biopsy findings. Case no. 9, who
presented with pain in the lower limbs and limp  -
ing in addition to short stature, persistent
hypocalcaemia with increased levels of parathyroid
hormone and alkaline phosphatase, and an X-ray
revealing osteoporosis, improved following a gluten-
free diet, the hypocalcaemia improved and jejunal
biopsy revealed normal villi with no flattening. This
is in agreement with Stazi et al. [27], who reported
that osteoporosis is an atypical presentation of CD.
Case no. 3, who presented with chronic diarrhoea
and congenital myopathy, showed slight
improvement of jejunal biopsy, i.e. villous atrophy
changed from grade III to grade II, AGA-IgG
remained positive but both diarrhoea and myopathy
were improved. This is probably related to poor
compliance of the patient. Also, this is in agreement
with Cakir et al. [28], who reported that the rate of
neurological problems is increased in children with
CD. Neurological abnormalities should be carefully
investigated early after the diagnosis of CD is made.
Coeliac disease is a life-long inflammatory
autoimmune condition of the gastrointestinal tract
affecting genetically susceptible individuals. The
coexistence of CD and other autoimmune disorders,
particularly IDDM, thyroid disease and dermatitis
herpetiformis, has been reported by several authors
[17, 29, 30].
Screening of IDDM patients in our study for CD
revealed that 6/200 (3%) (5 females and 1 male)
had CD as confirmed by jejunal biopsy. The most
frequently encountered clinical presentation of the
CD cases in this study was GIT manifestations (5/6,
83.3%) in the form of repeated vomiting, abdominal
distention and recurrent diarrhoea followed by
anaemia with short stature (2/6, 33.3%) and
repeated urinary tract infection (1/6, 16.6%). This
agrees with Magazzu et al. [31], who reported that
among 250 IDDM studied patients, 8/250 (3.2%)
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have CD, 7/8 (87.5%) presented with GIT
manifestations and 1/8 (12.5%) presented with
short stature. In contrast, Kaspers et al. [32] found
that children with type 1 diabetes and CD were
characterized by earlier onset of diabetes and
decreased growth and weight gain. 
The prevalence of CD in this study among 200
IDDM patients was nearly similar to that reported
by Barera et al. [33] (3.2%). However, it is lower than
that reported by Salah et al. [34] (4%), Goh and
Banerjee [35] (4.4%) and Novoa Medina et al. [36]
(8%). The prevalence of CD in our study among
IDDM patients was based on the results of
intestinal biopsy. But still this prevalence does not
reflect the actual prevalence of CD because a biopsy
specimen was not taken for all IDDM patients. 
Follow-up serological screening after 9-11 months
of a gluten-free diet (GFD) in CD patients (group III)
revealed that all serological markers are still
positive. Two explanations for this finding are
possible: first, poor compliance of patients to GFD
is a possibility, as there are difficulties in sticking
to a GFD in Egypt, it being less commercially
available and more expensive. Secondly, serological
screening follow-up was performed after 9-11
months on a GFD, which may not be sufficient for
serological markers to disappear from the serum.
Mäki et al. [37] reported that IgG AGA needs a long
time, sometimes more than one year, to become
negative. EMA was reported to persist for about 
9 months, while ARA disappears in parallel with
mucosal healing [38].
The standard diagnostic criteria of CD included
the presence of the characteristic anti-gliadin or
anti-tissue transglutaminase antibodies in serum,
flattened mucosa on intestinal biopsy, and
improved symptoms on a gluten-free diet [39].
In our study, serological screening tests for CD
of all studied patients revealed that IgA EMA, IgG
TTG, AGA (IgA), AGA (IgG) and ARA had sensitivity
rates of 70.6, 72.7, 17.0, 80.0, 57.5%, respectively;
the specificity rates were 94.7, 85.7, 93.2, 92.9 and
95.6%; positive predictive values were 52.2, 80.0,
57.1, 64.0 and 67.6%; and negative predictive values
were 97.5, 80.0, 68.3, 96.7 and 93.4%, respectively.
Yachha el al. [40] found that IgA EMA, IgA TTG,
AGA (IgA) and AGA(IgG) had sensitivity rates of 83,
74, 61 and 74%, respectively; the specificity rates
were 95, 100, 89 and 26%; positive predictive values
were 95, 100, 88 and 55%; and negative predictive
values were 82, 74, 65 and 45%, respectively. They
concluded that IgA TTG is useful for the diagnosis
of CD, with sensitivity and specificity rates
comparable to those of EMA, and this test is well
suited for use in tropical countries such as India.
The present findings of lower sensitivity of AGA
(IgA), EMA and ARA may be attributed to poor
immune response of patients or IgA deficiency,
which was not tested for in the present study
group, age dependency of both IgG AGA and EMA,
different cut-off values of the serological antibodies
as regards AGA, or variation in the interpretation of
immunofluorescence used for both ARA and EMA.
Hill and Holmes [41] reported that the diagnostic
guidelines could be modified so that small bowel
biopsy is no longer regarded as mandatory in patients
with high tTG. This will avoid invasive procedures and
may lead to more rapid diagnosis and earlier
treatment for over half of new patients with CD. On
the other hand, Rodrigues and Jenkins [13] reported
that the diagnosis of CD still requires upper
gastrointestinal endoscopy and small bowel biopsy. 
However, patients with other autoimmune
diseases, such as autoimmune hepatitis and
diabetes mellitus, can react positively with tTG by
ELISA [42]. In addition, CD can occur in patients with
IgA deficiency with an incidence 10-15-fold higher
than the general population. In patients with IgA
deficiency with CD, IgA antibodies to gliadin,
endomysium, reticulin and tTG are usually negative.
Such patients with IgA deficient CD are positive for
IgG AGA. However, not all IgA deficient patients with
CD are positive for IgG AGA. Thus, IgG EMA and IgG
tTG are useful screening tests especially in patients
with IgA deficiency [43].
A limitation of our study was the number of
patients and written consent from parents of
children for doing jejunal biopsy and cost of kits. 
In conclusion, coeliac disease is more common
in Egyptian children with refractory iron deficiency
anaemia, non-endocrinal short stature and type 1
diabetes than was previously thought. Screening of
high-risk groups, and of patients with such
common symptoms, is becoming an accepted
standard in practice.
Coeliac disease is frequently under-diagnosed
because of its protean presentations. Serological
tests showed fairly good sensitivity and specificity
in our study. The advent of serological markers with
high sensitivity and specificity is changing our
understanding of the disease and its prevalence.
However, intestinal biopsy remains the cornerstone
for definitive diagnosis of CD in patients with
immunological reaction to gluten.
From this study, we suggest that the basis for
diagnosis of CD in children should be through early
case-finding by a) knowledge about different
presentations of the disease and factors affecting
them, b) generous serological testing in patients with
vague symptoms, and c) screening of risk groups. 
Encouragement of diagnosed children and
adolescents with CD to receive a gluten-free diet to
prevent the occurrence of serious complications
attributed to this disease is highly recommended.
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